Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (BCTX)
NASDAQ:BCTX
BCTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.00 - $294.46
Previous Close$0.41
Volume996.24K
Average Volume (3M)103.22K
Market Cap
C$14.59M
Enterprise Value$5.00M
Total Cash (Recent Filing)C$12.46M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 23, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.85
Shares Outstanding1,755,109
10 Day Avg. Volume118,343
30 Day Avg. Volume103,223
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$40.00Price Target Upside447.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyBria-IMT regimen demonstrates promising overall survival and clinical benefit across subtypes of metastatic breast cancer.
Clinical TrialsBria-IMT Phase 3 trial progresses with new key sites added for enrollment, increasing the speed for enrollment.
Regulatory ApprovalThe Phase 3 trial, if positive, could result in full FDA approval and marketing authorization of Bria-IMT in metastatic breast cancer.
Bears Say
Financial PerformanceBriaCell had FY2Q25 operating expenses of $7.2M which were higher than expenses from FY1Q25, likely due to acceleration of enrollment in the Bria-IMT Phase 3 trial.
BriaCell Therapeutics News
BCTX FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was $6.00 and its highest was $294.46 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$14.59M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Oct 23, 2025 which is in 54 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Jun 16, 2025. The company reported -$16.851 earnings per share for the quarter, missing the consensus estimate of N/A by -$16.851.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Undervalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 1,755,109 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -$16.851 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.269%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in BCTX
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$40.00 (447.97% Upside)
C$40.00 (447.97% Upside)
Blogger Sentiment
Bullish
BCTX Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.58%
12-Months-Change
Fundamentals
Return on Equity
-608.22%
Trailing 12-Months
Asset Growth
175.56%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
BCTX Stock 12 Month Forecast
Average Price Target
$40.00
▲(447.97% Upside)
Technical Analysis
Rapid Dose Therapeutics Corp
―
PharmaTher Holdings Ltd
―
NurExone Biologic
―
Defence Therapeutics
―
Thiogenesis Therapeutics Corp
―
Ownership Overview
44.49% Insiders
<0.01% Mutual Funds
0.23% Other Institutional Investors
99.77% Public Companies and
Individual Investors